 Really, the only way we have of detecting pancreatitis and pancreatic cancer is through vague symptoms and a blood test called CA-199, and you can measure CA-199 in the blood of patients with pancreatitis and pancreatic cancer, and what you can see is that when the disease worsens, your CA-199 levels go up. And so I ask the very basic question, what is CA-199, and does it do anything? So for the first time we did the experiment that showed CA-199 elevation can actually cause inflammation in the pancreas. Without reduction in CA-199 levels, this leads to a wound that never heals, and this will eventually progress to transformation of the pancreas and basically open the gateway to developing pancreatic cancer. So even though elevation of CA-199 is bad, it represents a unique opportunity for a new therapeutic target. So what we did in this study was use CA-199 blocking antibodies to reduce the severity of pancreatitis and prevent it from reaching higher levels of severity. So it's a way of treating pancreatitis that we really never had before and represents a way of actually not just treating existing pancreatitis, but theoretically preventing it from occurring in patients at risk.